Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas

Area of Science:

• Oncology
• Pharmacology

Background:

• Soft-tissue sarcomas are a group of rare cancers.
• Advanced stages often require systemic treatment.
• Fludarabine phosphate is an antineoplastic agent.

Purpose of the Study:

• To evaluate the efficacy and toxicity of fludarabine phosphate in patients with advanced soft-tissue sarcomas.
• To determine response rates and survival outcomes.

Main Methods:

• A phase II clinical trial was conducted.
• Twenty-three patients with advanced soft-tissue sarcomas received fludarabine phosphate.
• Dosing varied based on renal function (100 mg/m2 or 125 mg/m2 every 3 weeks).

Main Results:

• No complete or partial responses were observed in 20 evaluable patients.
• The median survival was 12 weeks.
• Leukopenia was the most frequent adverse event.

Conclusions:

• Fludarabine phosphate, at the tested doses and schedule, did not demonstrate therapeutic efficacy in this patient population.
• Further investigation of fludarabine phosphate for advanced soft-tissue sarcomas is not warranted based on these findings.